Saturday, March 18, 2017 11:48:17 AM
I will give Bryce credit on this because I had already written this situation off as it was going to happen in this fashion ( meaning the six month review ). It is not a 100% fool proof situation. I reviewed their own 10K yesterday - again. I found no mention of a six month review anywhere in the document. It did however mention a 10 month review preceded by a 60 day wait period - in order to review if the NDA is acceptable. With a notation that often times the FDA takes even longer.
This information is vital to my investment plans. It should also be vital to anybody that still has shares. The longer the wait, the more money that is going to be needed. Remember also that they are keen on keeping the NASDAQ listing, so that means they have to stay above the $2.5 m shareholder equity.
Like other people have said, it's all about FDA approval of Vitaros. Yeah, that's the end game. The question that everybody should be asking themselves is how much money is it going to take to allow the company to be still standing when that happens. That from a cost standpoint. And what is it worth if it's approved ( two scenario's upon possible approval that do not command the same valuation - Allergan opt in or not ).
The problem with most of the people on this board is that they want to concentrate on the possible reward. What about the necessary costs? Hasn't anybody learned anything from past experiences with this same company? Somehow management is to execute in a flawless fashion - this time around. When experience has taught us that they don't.
I could make a list of current management's self imposed goals and show you just how many they have failed on over the years. But this time it has to be different. Why? Because there is nothing left if they don't execute?
Recent SEEL News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/14/2024 09:50:49 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 09:01:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 01:10:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:59:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:54:15 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:54:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/15/2023 09:06:26 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 09:05:27 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM